Article Type : Review Article
Authors : Yadav M, Dahiya M, Rawat N and Kumar A
Keywords : mTOR; Schizophrenia; Memory; Epilepsy; Depression
mTOR signalling pathways entailed in the pathophysiology of
various neurological disorders such as schizophrenia, cognition deficient,
epilepsy, depression etc. mTOR controls cell growth and involve in the
metabolism, cellular energy, nutrients including cell growth. Growing evidences
highlight that alteration of mTOR signaling can affect various pathways such as
cellular energy production, glucose metabolism, cell growth and mitochondrial
functions etc. Deregulation of mTOR contributes significantly in the
development of neurological and neurodegenerative disorders. Targeting brain
mTOR pathway may therefore have been proposed as an emerging drug target for
several neurological problems. However, challenges are still exist for a
successful drug development targeting mTOR. The present review is an attempt to
discuss the regulation of mTOR signalling and its emerging role in various
neurological disorders.
mTOR
(Mammalian target of rapamycin) is a serine/threonine kinase molecular complex
with a 289-kDa molecular weight which acts through the PI3K-related kinase
(PIKK) family. It was identified as a mechanistic target of rapamycin drug
(lipophilic macrolide compound synthesized by Streptomyces hygroscopicus
bacterium) on the bases of this referred to as mTOR [1]. It has been studied
that reduced mTOR signalling can lead to neurological disorders, whereas
hyperactivation of mTOR cascade can lead to abnormal growth of neurons and glia
that further can cause malfunctioning of the brain [2]. Catalytic subunit of
mTOR communicates with various proteins and forms two functionally complexes
known as mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2). These mTOR complexes
composed of a catalytic subunit (small protein known as mLSt8), which is a core
protein for mTORC1 and mTORC2 along with these two more components like
Tti1/Tel2 regulatory proteins that make a scaffold for the selection of
substrates and the negative regulator Deptor, which prevent the binding of
substrate. There are some growth factors or environmental stimulus, which
potentiate the activation of mTOR via PI3K/PTEN/Akt pathway [3]. Moreover,
growth factors and insulin binding to tyrosine kinase receptors (RTKs) and
activate the lipid kinase PI3K, which phosphorylates the
phosphatidylinositol-4,5-phosphate (PIP2) for the synthesis of
phosphatidylinositol-3,4,5-phosphate (PIP3), which further contributes to
activate the PDK1 (3-phosphoinoitide-dependent protein kinase 1) and Akt is
subsequently activated via phosphorylation resulting in inhibition of TSC2 that
acts as a downstream regulator of mTORC2 (mammalian target of rapamycin complex
2) through inhibition of Rheb which is an activator of mTORC2. Activated Akt
involve in the phosphorylation of various molecules including GSK-3 which is
responsible for glucose metabolism, neuronal differentiation and development,
synaptic plasticity, intracellular trafficking, apoptosis and regulation of
gene transcription [4]. Most of the pathways that stimulate mTORC1 collectively
inhibit the TSC1-TSC2 (hamartin-tuberin) complex, a heterodimer which act as a
potent endogenous mTOR inhibitor, whereas amino acids activate mTORC1
independently from TSC complex. Specifically, mTORC1 activation is occurred by
blocking TSC complex through its phosphorylation on specific sites via various
kinases like canonical Akt, ribosomal S6 kinases (RSK), or even IKKB (I?B
kinase ?) [5]. Upon activation it contributes in synthesis, ribosome and lipid
biogenesis. AMPK (AMP-dependent kinase) is another mechanism entailed in the
regulation of mTOR signalling. It is activated by a high AMP/ATP ratio which
acts as a key sensor for the energy status in the cell upstream of mTOR.
Initially, it phosphorylates and stimulates TSC2 function to inhibit mTOR
activity additionally it can directly block mTORC1 by phosphorylating raptor.
Hence, lack of energy states where the AMP/ATP ratio is high as a result of
increased AMPK activity and suppression of mTOR based growth pathways (Figure
1) [6,7].
Schizophrenia
Reelin is a glycoprotein secreted by cajal retzius
cells to control cortical layering and by hippocampal GABAergic and cerebellar
glutaminergic granular cells in the adult brain to maintain neural networks.
There is significant downregulation of reelin expression in psychosis by
inducing recruitment of Akt and PI3K via phosphorylation of disrupted-in-schizophrenia
1 (DISC1) that regulate cell arrangement during the
development of the brain. Since, mTOR signalling cascade has not directly
involved in the development of cortical, but it has trophic effects on
hippocampal dendrite growth and branching by regulating expression of reelin
[8]. Moreover, BDNF induced activation of the mTOR signalling pathway and
involved in the cognitive process [9]. Therefore, any disruption in the
signalling of mTOR pathway either depressed or overactive has a significant
pathological role in psychosis or schizophrenia. The disrupted in schizophrenia
1 (DISC1) gene codes for a scaffolding protein which interacts with the various
cellular proteins to alter their functional activities at several stages of
neurodevelopment. Further, mTOR signalling is negatively regulated by DISC1,
where DISC1 knockdown mice possess abnormal morphology and excitability of
neuronal networks, deficits in aspects of cognition, depressive along with
anxiety-like behaviors of schizophrenia [10].
Learning
and memory
mTOR involved in the
neural functioning of CNS like learning and memory that achieved by long-term
synaptic plasticity (long term potentiation). A study on Aplysia and crayfish
and rat hippocampal slices demonstrate that treatment to rapamycin blocked long-term
synaptic plasticity and interfere with normal learning and memory functions.
Genetic ablation of mTOR inhibitors FKBP12 and S6K1 not completely mimic the
action of rapamycin [11]. mTORC1 also cause long term depression similar to
activation of metabotrophic glutamatergic receptor causing long term depression
(LTD) by increasing the level of MAP kinase and PI3- kinase-mTOR signalling and
protein synthesis synapse, consistent blocking mTOR signalling block the mGlu-R
dependent LTD [12]. mTORC2 control the actin cytoskeleton in non-neuronal cell
and play important role in regulating the neuronal process rapamycin treatment
reverse the behavioral phenotype of TSC1/2(Tuberous Sclerosis Complex (TSC)) mutant mice suggest that both
mTORC1and mTORC2 to regulate the synaptic physiology and behavior [13].
Epilepsy
As the mTOR signalling
regulates protein synthesis, synaptic plasticity decreases the pathological
abnormality occurs in epilepsy it can be hypothesized that mTOR also involved
in the mechanism of epileptogenesis in TSC patients. Inhibitors of mTOR
signalling have antiepileptogenic property that provides satisfactory treatment
of epilepsy. Treatment of rapamycin prevents the development of epilepsy and
other pathological and molecular changes that likely promote epileptogenesis.
In TSC models of epilepsy, seizure return within a week of rapamycin therapy
cessation which suggest that beneficial effect of rapamycin on seizure not
persist if rapamycin is stopped and the intermittent rapamycin treatment can
treat epileptogenesis [14].
Depression
Several studies reported
a decrease in the activation phosphorylated mTOR in animal model of
depression-like in chronic unpredictable stress (CUS) model of depression in
mice and rat shows a reduced level of phosphorylated mTOR and its downstream
signalling components such as Phosphor-P70S6K in prefrontal cortex hippocampus
and amygdala. Acute administration of ketamine increasing the brain-derived
neurotrophic factor and phosphorylated mTOR in hippocampus of rat and shows
antidepressants property in force swim test (FST). Some other modulators like
ascorbic acid, creatin, zinc, erythropoietin, scopolamine also shows
antidepressant property by increasing the amount of phosphorylated mTOR in the
brain [15,16].
Role of mTOR signaling
has been well reported in other neurological problems particularly neurodegenerative
diseases [17]. Varous neurodgenrative disease such as Parkinson, huntington,
autism, Alzheimer disease are occurred to accumulation of misfolded protein
leading to lose of memory, tremor and motor incorordinatoon.
mTOR is a serine/
threonine kinase has mTOR has an emerging role in brain disorders. It is found
in two functionally complexes, which regulates various functions like protein
synthesis, lipid metabolism, energy metabolism, autophagy, mitochondria etc.
Moreover, it’s signalling also controls regulate synaptic plasticity, neuronal
development, memory formation, and cognition. Hence, it is seen that mTOR has
an emerging role in brain disorders. Preclinical as well as clinical
investigation suggested that mTORC1 inhibitors have therapeutic role in
psychosis, cognitive impairment and epilepsy, while activation of mTORC1 can be
helpful in depression, axonal growth and regeneration.
Acknowledgement
Authors would like to
thank the financial support of SERB-DST (PDF/2018/002605), Government of India.
Conflict of Interest
The authors declare no
conflict of interest.